Mangoceuticals, Inc. (MGRX)
NASDAQ: MGRX · Real-Time Price · USD
0.3848
-0.0812 (-17.42%)
At close: Sep 28, 2026, 4:00 PM EDT
0.3880
+0.0032 (0.83%)
Pre-market: Sep 29, 2026, 6:27 AM EDT

Mangoceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
0.320.460.620.730.01-
Revenue Growth
-38.91%-25.96%-15.81%8083.16%--
Cost of Revenue
0.140.210.240.30-
Gross Profit
0.170.250.380.430-
Selling, General & Admin
3.845.935.546.3920.07
Amortization of Goodwill & Intangibles
1.121.120.72---
Operating Expenses
13.3317.848.628.5520.07
Operating Income
-13.16-17.59-8.24-8.12-1.99-0.07
Interest Expense
-0.65-0.1-0.01--0.01-0
Interest & Investment Income
---0.01--
Other Non Operating Income (Expenses)
-0.04-1.56-0.45-1.1--
EBT Excluding Unusual Items
-13.84-19.26-8.71-9.21-2-0.07
Asset Writedown
-1.24-1.24----
Legal Settlements
0-0.13----
Other Unusual Items
-0.02-0.02----
Pretax Income
-15.1-20.64-8.71-9.21-2-0.07
Earnings From Continuing Operations
-15.1-20.64-8.71-9.21-2-0.07
Minority Interest in Earnings
000---
Net Income
-15.1-20.64-8.71-9.21-2-0.07
Preferred Dividends & Other Adjustments
1.181.180.8---
Net Income to Common
-16.28-21.82-9.51-9.21-2-0.07
Net Income Growth
------
Shares Outstanding (Basic)
15102111
Shares Outstanding (Diluted)
15102111
Shares Change
208.91%408.93%84.23%49.22%34.98%-
EPS (Basic)
-1.10-2.17-4.80-8.58-2.78-
EPS (Diluted)
-1.10-2.17-4.80-8.58-2.78-
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-3.89-5.85-4.86-7-1.39-0.07
Free Cash Flow Per Share
-0.26-0.58-2.46-6.52-1.93-0.13
Gross Margin
54.43%54.91%61.70%58.99%54.26%-
Operating Margin
-4173.65%-3858.11%-1337.90%-1109.84%-22279.70%-
Profit Margin
-5164.40%-4784.65%-1543.87%-1259.40%-22352.11%-
Free Cash Flow Margin
-1234.31%-1282.89%-789.74%-957.07%-15545.59%-
EBITDA
-12.1-15.87-7.51-8.09-1.99-
D&A For EBITDA
1.061.720.730.020-
EBIT
-13.16-17.59-8.24-8.12-1.99-0.07
SEC Filings: 10-K · 10-Q